EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion

Olga M Rusiecka, Filippo Molica, Linda Clochard, Raf Van Campenhout, Timo W M De Groof, Viviane Bes, Nick Devoogdt, Serge Muyldermans, Mathieu Vinken, Brenda R Kwak

Cell and Tissue Research · 2025-10 · 402 (1) · 121-137

DOI: 10.1007/s00441-025-03994-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell and Tissue Research, online erschienen am 23.07.2025. Verfasst von Olga M Rusiecka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Connexins, Myocardial Reperfusion Injury, Single-Domain Antibodies, Nerve Tissue Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation Flanders, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Gabbiani fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reperfusion following myocardial infarction salvages the ischemic heart but paradoxically exacerbates injury. Yet, efficient treatment for cardiac ischemia/reperfusion injury is still missing in clinics. ATP release through Pannexin1 (PANX1) channels facilitates recruitment of leukocytes to the injured myocardium. Thus, PANX1 channel inhibition might confer cardioprotection. Currently available PANX1 channel blockers lack specificity or in vivo stability. Nanobodies offer a new therapeutic modality given their high target affinity, small size, and deep tissue penetration. Nanobodies targeting Panx1 were recently introduced. Here, their target specificity and selective PANX1 channel inhibition for cardiovascular purposes were validated in vitro. The two most promising candidates were further examined in the context of cardiac ischemia/reperfusion injury. Nanobody-1 (Nb1) and Nb9 reduced neutrophil adhesion to an endothelial monolayer. Nb1 did not affect left ventricular function ex vivo; however, Nb9 tended to diminish the performance of isolated hearts. Finally, in vivo application of Nb1, but not of Nb9 or a control Nb, at the onset of reperfusion increased the survival rate of mice. However, the infarct size observed after treatment with Nb1 was similar than the one found after treatment with the control Nb. In conclusion, Nb1 efficiently and specifically inhibits ATP release from endothelial cells thereby limiting leukocyte adhesion and improving the outcome of cardiac ischemia/reperfusion in mice. This warrants further studies to unveil the detailed molecular mechanism underlying the beneficial effects of Nb1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConnexinsMyocardial Reperfusion InjurySingle-Domain AntibodiesNerve Tissue ProteinsAnimalsHumansMiceMice, Inbred C57BLMaleAdenosine TriphosphateCell Adhesion

Stichwörter der Autor:innen

Cardiac ischemia/reperfusionChannelsEndothelial cellsNanobodiesPannexin1

Substanzen

ConnexinsSingle-Domain AntibodiesNerve Tissue ProteinsAdenosine TriphosphatePanx1 protein, mouse

Autor:innen und Institutionen

  • Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Geneva Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Filippo.Molica@unige.ch.
  • Geneva Center for Inflammation Research, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Filippo.Molica@unige.ch.
  • Department of Pharmaceutical and Pharmacological Sciences, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
  • Molecular Imaging and Therapy Research Group, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.

Förderung

  • Research Foundation Flanders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Gabbiani fund
  • Flemish Government
  • University of Geneva

Zitieren

APA

Rusiecka, O. M., Molica, F., Clochard, L., Van Campenhout, R., De Groof, T. W. M., Bes, V., Devoogdt, N., Muyldermans, S., Vinken, M., & Kwak, B. R. (2025). Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion. Cell and Tissue Research, 402(1), 121-137. https://doi.org/10.1007/s00441-025-03994-y

Vancouver

Rusiecka OM, Molica F, Clochard L, Van Campenhout R, De Groof TWM, Bes V, et al. Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion. Cell and Tissue Research. 2025;402(1):121-137. doi:10.1007/s00441-025-03994-y

BibTeX
@article{Rusiecka2025,
  author = {Rusiecka, Olga M and Molica, Filippo and Clochard, Linda and Van Campenhout, Raf and De Groof, Timo W M and Bes, Viviane and Devoogdt, Nick and Muyldermans, Serge and Vinken, Mathieu and Kwak, Brenda R},
  title = {Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion},
  journal = {Cell and Tissue Research},
  year = {2025},
  volume = {402},
  number = {1},
  pages = {121--137},
  doi = {10.1007/s00441-025-03994-y}
}
Kostenlos starten →